Zhejiang Jolly PharmaceuticalLTD Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Tao Wang

Algemeen directeur

CN¥1.1m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	6.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	5.3yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Investors Still Aren't Entirely Convinced By Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings Despite 32% Price Jump

Oct 17

These 4 Measures Indicate That Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Is Using Debt Safely

Oct 06

It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

Aug 30

We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease

Jul 29

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

May 13

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

May 08

There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Mar 01

CEO

Tao Wang (56 yo)

6.8yrs

Tenure

CN¥1,092,500

Compensatie

Mr. Tao Wang serves as General Manager at Zhejiang Jolly Pharmaceutical Co., Ltd. since January 16, 2018 and has been its Non-Independent Director since May 10, 2024 and also served as its Senior Manager a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Tao Wang	GM & Non-Independent Director	6.8yrs	CN¥1.09m	geen gegevens
Yuehong Shen	Deputy GM & Non-Independent Director	3.8yrs	CN¥743.10k	geen gegevens
Guofu Feng	Executive Deputy GM	2.6yrs	CN¥807.50k	0.095% CN¥ 10.9m
Jian Chen	Deputy General Manager	16.8yrs	CN¥606.70k	0.15% CN¥ 17.2m
Xiao Guo Peng	Deputy General Manager	6.8yrs	CN¥711.50k	geen gegevens
Xin Tan	Deputy General Manager	1.8yrs	CN¥721.30k	0.0028% CN¥ 315.5k

5.3yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300181 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Tao Wang	GM & Non-Independent Director	less than a year	CN¥1.09m	geen gegevens
Yuehong Shen	Deputy GM & Non-Independent Director	3.8yrs	CN¥743.10k	geen gegevens
Guofu Feng	Executive Deputy GM	7.8yrs	CN¥807.50k	0.095% CN¥ 10.9m
Youqiang Yu	Chairman	21.3yrs	CN¥1.03m	18.92% CN¥ 2.2b
Huifen Zhang	Non-Independent Director	3.8yrs	CN¥20.00k	geen gegevens
Xuegen Zheng	Non-Independent Director	16.8yrs	CN¥20.00k	0.11% CN¥ 12.1m
Jian Jun Wang	Non-Independent Director	7.8yrs	CN¥20.00k	geen gegevens
Bin Pan	Independent Director	4.7yrs	CN¥60.00k	geen gegevens
Ping Wang	Independent Director	3.8yrs	CN¥60.00k	geen gegevens
Jian Zhu	Independent Director	3.8yrs	CN¥60.00k	geen gegevens
Chenghua Zhou	Chairman of the Supervisory Board	6.8yrs	geen gegevens	geen gegevens
Jie Yao	Independent Director	less than a year	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300181 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Zhejiang Jolly PharmaceuticalLTD Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Zhejiang Jolly Pharmaceutical Co.,LTD, Annual General Meeting, May 10, 2024

Insufficient new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Management Appointments

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.13 in 3Q 2023)

Investors Still Aren't Entirely Convinced By Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings Despite 32% Price Jump

These 4 Measures Indicate That Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Is Using Debt Safely

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Q3, 2024 Results on Oct 28, 2024

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.14 in 2Q 2023)

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) announces an Equity Buyback for CNY 300 million worth of its shares.

We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease

Now 21% undervalued after recent price drop

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2024 Results on Jul 30, 2024

New minor risk - Share price stability

Dividend increased to CN¥0.45

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 1Q 2023)

Zhejiang Jolly Pharmaceutical Co.,LTD, Annual General Meeting, May 10, 2024

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Q1, 2024 Results on Apr 19, 2024

Investor sentiment improves as stock rises 18%

Now 22% overvalued after recent price rise

There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Investor sentiment deteriorates as stock falls 16%

Insufficient new directors

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.11 in 2Q 2022)

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2023 Results on Aug 09, 2023

Zhejiang Jolly Pharmaceutical Co.,LTD Announces Cash Dividend on A Shares for the Year 2022, Payable on 30 May 2023

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Cash Dividend for 2022

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings released: EPS: CN¥2.25 (vs CN¥0.29 in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.074 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.07 in 2Q 2021)

Investor sentiment improved over the past week

Zhejiang Jolly Pharmaceutical Co.,LTD Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 31 May 2022

Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Cash Dividend for 2021

High number of new and inexperienced directors

Zhejiang Jolly Pharmaceutical Co.,LTD Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorated over the past week

Zhejiang Jolly Pharmaceutical Co.,LTD announced that it expects to receive CNY 910 million in funding

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.074 (vs CN¥0.052 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.033 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Zhejiang Jolly Pharmaceutical Co.,Ltd Announces Final Cash Dividend for 2020, Payable on 31 May 2021

Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.15 (vs CN¥0.042 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: CN¥6.86

Full year 2020 earnings released: EPS CN¥0.14 (vs CN¥0.042 in FY 2019)

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Fiscal Year 2020 Results on Apr 13, 2021

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Management Appointments

Investor sentiment improved over the past week

New 90-day low: CN¥5.87

New 90-day low: CN¥6.12

New 90-day low: CN¥6.59

Third quarter earnings released

New 90-day high - CN¥8.10

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥6.39

CEO

Tenure

Compensatie

Leiderschapsteam